No additional high-impact, biotech-industry–specific regulatory, clinical, or commercial stories remained after filtering the provided list down to events directly relevant to biotech decision-makers. The remaining articles were either non-biotech/general healthcare policy commentary, non-actionable research without clear translational linkage for the biotech audience, or non-industry content. This section is intentionally left unused to maintain strict topical diversity and ensure all included items reflect biotech-relevant developments.